How a certain bacterium communicates and makes us sick

Phys.org | February 25, 2019

Researchers at Binghamton University, State University of New York have uncovered the unique way in which a type of Gram-negative bacterium delivers the toxins that make us sick. Understanding this mechanism may help design better ways to block and eventually control those toxins. Assistant Professor Xin Yong and graduate student Ao Li from the Department of Mechanical Engineering, along with Associate Professor Jeffrey W. Schertzer from the Department of Biological Sciences, published their findings in the Journal of Biological Chemistry.
The study looked at how bacteria communicate via the transportation of small molecules. Yong and Schertzer explained that communication molecules stimulate the production of outer membrane vesicles. These small packages then bud off from the surface of the bacterium and contain highly concentrated toxins. Originally, it was hypothesized that the communication molecule induced vesicle production by controlling gene expression, but that's not what's going on.

Spotlight

This infographics related to the  steam cell in molecular biotechnology. in which explain the all the molecular biotech proccess.

Spotlight

This infographics related to the  steam cell in molecular biotechnology. in which explain the all the molecular biotech proccess.

Related News

MEDICAL

Suono Bio, Inc. Announces Formulation-Agnostic Platform for the Delivery of RNA Therapeutics

Suono Bio | January 06, 2022

Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract. This latest publication adds to the validation of Suono Bio’s therapeutic delivery platform leveraging low-frequency ultrasound for formulation-agnostic delivery. This technology was originally developed in the laboratory of Institute Professor Robert Langer at MIT to facilitate rapid, local administration of therapeutics to treat serious diseases. “Therapeutic translation of oligos has been hampered by delivery and bioavailability issues with a complicated landscape for chemical-based formulations. This further demonstrates our capability to deliver RNAs and siRNAs to knockdown relevant gene targets without the need for any formulation.” Dr. Carl Schoellhammer, corresponding author, and Suono Bio co-founder In addition to previously demonstrating the preclinical use of siRNAs for treating inflammatory conditions, this latest publication demonstrates the ability to knockdown endogenous genes, including Ctnnb1, the gene encoding for beta-catenin, which plays a role in tumorigenesis in colorectal cancers, for example. ABOUT SUONO BIO Suono Bio was founded by Robert Langer and Giovanni Traverso, a gastroenterologist and biomedical engineer from the Department of Mechanical Engineering, MIT and Brigham and Women’s Hospital, Harvard Medical School, and Dr. Carl Schoellhammer. The company is developing therapeutic products for inflammatory-mediated diseases leveraging their ultra-rapid and formulation independent delivery technology. Suono Bio’s platform enables rapid, localized delivery of small molecules, biologics, and nucleic acids and gene therapies without the need for encapsulation of the therapeutic.

Read More

CELL AND GENE THERAPY

Taysha Gene Therapies Announces New Additions to Leadership Team to Deepen Manufacturing and Communications Capabilities

Taysha | December 30, 2020

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-driven gene therapy organization focused in on creating and commercializing AAV-based quality treatments for the treatment of monogenic infections of the focal sensory system in both uncommon and huge patient populaces, today reported new increases to its authority group with the arrangements of Greg Gara as Senior Vice President of Manufacturing and Kimberly Lee, D.O., as Senior Vice President of Corporate Communications and Investor Relations. Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy organization zeroed in on creating and commercializing AAV-based qgene therapies for the treatment of monogenic infections of the focal sensory system in both uncommon and huge patient populaces, today declared new increases to its authority group with the arrangements of Greg Gara as Senior Vice President of Manufacturing and Kimberly Lee, D.O., as Senior Vice President of Corporate Communications and Investor Relations.

Read More

MEDICAL

Fauna Bio's Comparative Genomics Approach Finds New Compounds for Heart and Lung Diseases

Fauna | June 15, 2022

Fauna Bio, a biotechnology company pioneering the fields of comparative, computational and translational genomics, is celebrating its fourth birthday this month with the release of Centaur, a knowledge graph that is the first of its kind to visualize the intersection between animal gene expression data and human diseases in one comprehensive map. With Centaur, Fauna Bio is able to more rapidly identify human disease indications and targets to generate new therapeutic solutions for some of the most serious human diseases. Orca is another new update to the Convergence platform, and enables direct comparison of gene expression signatures from naturally disease-resistant species with those from humans. Convergence now leverages genomic analyses across 452 mammal species (65 of which are hibernators), an 86 percent increase from two years ago. Much of the company's focus is cardiac and pulmonary diseases, where current treatments mainly focus on symptom management rather than treating the underlying condition. Faun1003, a compound discovered through LEO (Fauna Bio's drug prediction module), is being investigated for use in lung injury and pulmonary hypertension. While uniquely differentiated, retrospective analyses of similar compounds show a survival advantage in critical care settings for patients with lung injury that receive this drug, providing additional human support for the target of Faun1003. Fauna Bio's first neuronal program, Faun264G, looks to improve the survival of human neurons deprived of glucose. A pilot study found knockdown of 264G in-vivo impairs the ability of 13-lined ground squirrels to enter torpor, validating its function. Fauna will continue with expanded in-vivo experiments to understand its role in controlling metabolism this summer. Fauna Bio has also initiated a new discovery program in inflammatory bowel disease, seeking targets to improve epithelial barrier function and reduce immune cell migration. Forty-five percent of compounds predicted for use in IBD by LEO have already been investigated, suggesting strong enrichment for IBD targets. The company has also completed brain cortex and kidney sequencing, with target predictions coming soon. These updates build on the company's momentum since raising $9M in funding last year. Since then, Fauna has expanded partnerships with leading academic institutions, including the University of Wisconsin-Oshkosh and Monash University in Australia. Both collaborations focus on studying genes from the 13-lined ground squirrel that allow for survival during hibernation under extreme conditions. Monash University will assist in additional pre-clinical testing of Fauna compounds, while UW-O supports the existing colony, additional tissue collections, and in-vivo experiments. Through a new partnership with the University of Nevada - Las Vegas, Fauna will add genes from tenrecs, a second hibernating species, to Fauna Bio's proprietary biobank. We continue to see how the power of comparative genomics, and looking outside of our own species, is like building a stronger magnet to help us find that elusive needle in the haystack. By introducing a small amount of the right data and applying it in the right way, we can more quickly identify the real opportunities to make a difference for people suffering from diseases with unmet needs, We've had incredible support from the National Human Genomics Research Institute, the National Institute of Health, our investors, and advisors to continue educating and bringing these programs closer to finding real therapeutic solutions for many of the worst human diseases." Ashley Zehnder, Ph.D., D.V.M, CEO of Fauna Bio. About Fauna Bio Fauna Bio is an end-to-end target and drug discovery platform company and a pioneer in computational, comparative and translational genomics. Fauna Bio is mining the shared genetics between mammals and humans to pinpoint specific genes and pathways that result in disease resistance to some of the most common and deadly human diseases. With a proprietary biobank that includes thousands of tissue samples across multiple species and time points, unparalleled data curation, comparative genomics, machine learning-based target predictions and compound predictions, the Fauna Bio platform identifies extraordinary genes which are highly conserved across species and predicts small molecules that replicate disease resistance to jumpstart human drug development.

Read More